์ง๋ฐฉ ์ ์
์ ๋งฅ์ฃผ์ฌ์ฉ ์ง๋ฐฉ ์ ์ (ILE)๋ ์ฃผ๋ก **์ ๋งฅ ์์**์ ํตํด ๊ณ ๋ฐ๋ ์นผ๋ก๋ฆฌ์ ํ์ ์ง๋ฐฉ์ฐ์ ๊ณต๊ธํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋ค. ์์ ์๊ธ ์ํ์์๋ ์ง์ฉ์ฑ ์ฝ๋ฌผ(์: ์๋ฒ๋ฉํด๋ฅ, ๋ถํผ๋ฐ์นด์ธ๊ณผ ๊ฐ์ ๊ตญ์ ๋ง์ทจ์ ) ์ค๋ ์ ๋ํ **ํด๋ ์ **๋ก ์ ์ ๋ ๋ง์ด ์ฌ์ฉ๋๊ณ ์์ต๋๋ค. > **์์ ๊ฒฝ๊ณ :** ์ธ์๋ฆฐ ์ ํญ์ฑ(์: ๋น๋จ๋ณ)์ด ์๊ฑฐ๋ ์ท์ฅ์ผ ์ํ์ด ์๋ ํ์์๊ฒ๋ ๊ทน๋๋ก ์ฃผ์ํ์ฌ ์ฌ์ฉํด์ผ ํฉ๋๋ค. ์ ์ ๋ ๋ฏธ์๋ฌผ ์ฆ์์ ๊ฐ๋ ฅํ ์ด์งํ๋ฏ๋ก ์๊ฒฉํ ๋ฌด๊ท ์กฐ์์ด ํ์์ ์ ๋๋ค. **์์ ํ:** ์ค๋ ์น๋ฃ๋ฅผ ์ํ ILE ์ฌ์ฉ์ ์ข ์ข '์ง๋ฐฉ ๊ตฌ์กฐ(Lipid Rescue)' ์๋ฒ์ผ๋ก ๋ถ๋ฆฝ๋๋ค.
์์ฉ ๊ธฐ์ : As a nutritional supplement, lipid emulsions provide **triglycerides** which are hydrolyzed by **lipoprotein lipase** into free fatty acids and glycerol, entering cellular metabolism via **beta-oxidation** to produce ATP. As an antidote, the primary mechanism is the **'lipid sink' theory**: the infusion creates an expanded intravascular lipid phase that sequesters highly lipophilic toxins (e.g., bupivacaine, ivermectin) away from target organs (brain, heart) โ reducing clinical toxicity.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Parenteral nutrition ยท Supply 30% (partial peripheral) to 40-60% of energy requirements ยท IV ยท continuous ยท As required ยท Amount governed by physiological status
- Treatment of lipid-soluble toxicosis (e.g., ivermectin, moxidectin) ยท 1.5-5 ml/kg of 20% lipid solution as bolus, followed by 0.25-0.50 ml/kg/min infusion. Boluses of 1.5 ml/kg can be repeated. ยท IV ยท bolus followed by continuous infusion ยท Infusion for 30-60 min (maximum 24 hours) ยท Infusions of 0.5 ml/kg/min can be administered for a maximum of 24 hours.
- Parenteral nutrition ยท Supply 40-60% of energy requirements ยท IV ยท continuous ยท As required ยท Generally used as an energy source in a nutrient admixture for infusion through central venous access (total parenteral nutrition).
- Treatment of lipid-soluble toxicosis (e.g., ivermectin, moxidectin) ยท 1.5-5 ml/kg of 20% lipid solution as bolus, followed by 0.25-0.50 ml/kg/min infusion. Boluses of 1.5 ml/kg can be repeated. ยท IV ยท bolus followed by continuous infusion ยท Infusion for 30-60 min (maximum 24 hours) ยท Infusions of 0.5 ml/kg/min can be administered for a maximum of 24 hours.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Insulin resistance (e.g., diabetes mellitus)
- Hyperlipidaemia
- Disrupted fat metabolism
์ด์๋ฐ์
- Febrile episodes (mainly with 20% emulsions)
- Vasculitis
- Thrombosis
- Anaphylaxis (rare)
- Hepatic failure (with prolonged treatment)
- Pancreatitis (with prolonged treatment)
- Cardiac arrest (with prolonged treatment)
- Thrombocytopenia (with prolonged treatment)
์ฝ๋ฌผ ์ํธ์์ฉ
- Other IV medications ยท Physical incompatibility; requires dedicated IV line for parenteral feeding ยท major
- Biochemical assays ยท Lipaemia interferes with blood gas and calcium measurements if samples are taken before fat is cleared ยท moderate
๋ชจ๋ํฐ๋ง
- Plasma clearance (visual lipaemia or serum triglycerides daily)
- Blood glucose
- Pancreatic enzymes
- Coagulation profile (if prolonged use)
๊ณผ์ฉ๋
Overdosage or failure to clear lipids can lead to **fat overload syndrome**, characterized by hyperlipidaemia, fever, jaundice, hepatosplenomegaly, and coagulopathy. Treatment involves immediate cessation of the infusion and supportive care.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.